top of page

Advancing treatment of
severe inflammatory diseases


Intercepting activation of the NLRP3 inflammasome

Our drug discovery platform is focused on developing selective antagonists of the NLRP3 inflammasome, an inflammatory pathway critical to the development of a wide variety of diseases including acute lung injury, Acute Respiratory Distress Syndrome, Bronchopulmonary Dysplasia, systemic sepsis, acute liver and kidney injury, and pneumonia.

Our lead candidate, AZM-152, is a RHAMM-derived antagonist that blocks a key upstream priming signal involved in the aberrant activation of the NLRP3 inflammatory cascade.

Targeting severe inflammatory diseases with significant unmet needs

Initial indications target severe inflammatory pulmonary diseases with significant unmet needs.


For many inflammatory and fibrotic lung diseases, no effective preventative or therapeutic treatments exist.  With limited options for disease management, these severe and acute lung conditions exert a considerable burden on patients, families, and healthcare providers, including higher rates of mortality, longer lengths of stay in intensive care units, and life-long morbidities.

Acute Respiratory Distress Syndrome (ARDS) 

A serious lung disorder that occurs in response to various causes such as pneumonia, sepsis, or trauma, ARDS can lead to inflammation and lung damage resulting in severe respiratory failure.

Idiopathic Pulmonary Fibrosis (IPF)

Often unpredictable, acute exacerbations of this chronic lung disease worsen lung function, leading to significant morbidity and earlier mortality.

Bronchopulmonary Dysplasia (BPD)

Affecting premature infants who require mechanical ventilation and oxygen therapy and characterized by abnormal development and lung inflammation, BPD can lead to chronic pulmonary problems.  

Severe Viral Pneumonia

SARS-CoV-2 and influenza A-related pneumonia can lead to severe respiratory distress, acute respiratory distress syndrome (ARDS), and death.

Latest News

June 8, 2023

Azome data presented at Hyaluronan 2023

April 7, 2023

Azome announces appointment of Ulrich H. Von Andrian, MD to Scientific Advisory Board

March 6, 2023

Azome announces exclusive patent license

bottom of page